Stay updated on Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Added Gastric Cancer to the related topics section and included Genetic and Rare Diseases Information Center as a resources reference.
    Difference
    0.1%
    Check dated 2026-02-18T09:04:18.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Site updated to revision v3.4.2; a government funding/status notice previously shown (v3.4.1) has been removed.
    Difference
    0.3%
    Check dated 2026-02-11T10:57:49.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a government funding lapse notice with updated operating status for the NIH Clinical Center and updated the site version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-04T06:37:06.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    UI and metadata text on the study page were updated: a 'Show glossary' option was added, and new labels such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0' were introduced. The older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.
    Difference
    0.2%
    Check dated 2026-01-28T04:39:52.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision from v3.3.3 to v3.3.4 appears to be a minor template/UI update with no changes to the study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:51:29.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Expanded the Locations section with new study sites (Connecticut, District of Columbia, Illinois, Maryland, Massachusetts, Michigan, Missouri, North Carolina, Pennsylvania, Tennessee, Washington, Ontario, Quebec) and removed the previous location groupings.
    Difference
    1%
    Check dated 2025-12-23T20:44:02.000Z thumbnail image

Stay in the know with updates to Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Margetuximab Pembrolizumab Combo in HER2(+) Gastric Cancer Clinical Trial page.